1. Kuehl WM, Bergsagel PL. Early genetic events provide the basis for a clinical classification of multiple myeloma. Hematology/the Education Program of the American Society of Hematology. American Society of Hematology: Education Program, 2005:346–52.
2. Landgren O, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 2006;107:904–6.
3. Hutchison CA, et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nature reviews. Nephrology 2012;8:43–51.
4. SEER Stat Fact Sheets: Multiple Myeloma. Surveillance Epidemiology and End Results; National Cancer Institutes. Available at: http://seer.cancer.gov/statfacts/html/mulmy.html (Zugriff am 11. Juli 2013).
5. Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest 2012;122:3456–63.
6. Gorgun GT, et al. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood 2013;121:2975–87.
7. Podar K, et al. The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications. Br J Haematol 2011;155:438–48.
8. Chapman MA, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011;471:467–72.
9. Egan JB, et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 2012;120:1060–6.
10. Walker BA, et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia 2013: published online 2 July 2013, doi: 10.1038/leu.2013.199.
11. Keats JJ, et al. Clonal competition with alternating dominance in multiple myeloma. Blood 2012;120:1067–76.
12. Riccardi A, et al. Changing clinical presentation of multiple myeloma. Eur J Cancer 1991;27:1401–5.
13. Dimopoulos M, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia 2009;23:1545–56.
14. Terpos E, et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol 2013;18:2347–57.
15. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23:3–9.
16. Avet-Loiseau H, et al. Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myelome experience. J Clin Oncol 2013;22:2806–9.
17. Xiong W, et al. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood 2008;112:4235–46.
18. Drach J, et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 1998;92:802–9.
19. Avet-Loiseau H, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007;109:3489–95.
20. Shaughnessy J, et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with total therapy I: interpretation in the context of global gene expression. Blood 2003;101:3849–56.
21. Gertz MA, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and –17p13 in myeloma patients treated with high-dose therapy. Blood 2005;106:2837–40.
22. Gutierrez NC, et al. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 2007;21:143–50.
23. Fonseca R, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009;23:2210–21.
24. Zhou Y, et al. The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia 2009;23:1941–56.
25. Reed V, et al. Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy. Cancer 2011;117:4468–74.
26. Attal M, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91–7.
27. Child JA, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875–83.
28. Palumbo A, et al. Melphalan 200 mg/m² versus melphalan 100 mg/m² in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. Blood 2010;115:1873–9.
29. Straka C, et al. The effects of induction chemotherapy and high-dose melphalan with tandem autologous transplantation in multiple myeloma: the prospective randomized DSMM 2 study. Blood 2007;110: Abstract 446.
30. Attal M, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495–502.
31. Sonneveld P, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 2012;30:2946–55.
32. Boccadoro M, et al. LMPR versus MEL200: Lenalidomide maintenance versus no maintenance in newly diagnosed multiple myeloma. Proc ASCO 2013; Abstr. 8509.
33. Rajkumar SV, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431–6.
34. Harousseau JL, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005–01 phase III trial. J Clin Oncol 2010;28:4621–9.
35. Zonder JA, et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial. Blood 2010;116:5838–41.
36. Stewart AK, et al. How I treat multiple myeloma in younger patients. Blood 2009;114:5436–43.
37. Kropff M, et al. DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma. Ann Hematol 2009;88:1125–30.
38. Cavo M, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010;376:2075–85.
39. Garderet L, et al. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005–04 randomized phase III trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2012;30:2475–82.
40. Kumar S, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012;119:4375–82.
41. Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012;87:78–88.
42. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046–60.
43. Fayers PM, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1,685 individual patient data from 6 randomized clinical trials. Blood 2011;118:1239–47.
44. San Miguel JF, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol 2013;31:448–55.
45. Palumbo A, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366:1759–69.
46. Rajkumar SV, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010;11:29–37.
47. Shustik C, et al. A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. Br J Haematol 2007;136:203–11.
48. Myeloma Trialists’ Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4,012 patients. Br J Haematol 2001;113:1020–34.
49. Rosinol L, et al. Maintenance therapy after stem-cell transplantation for multiple myeloma with bortezomib/thalidomide vs. thalidomide vs. alfa2b-interferon: Final results of a phase III pethema/GEM randomized trial. ASH 2012: Abstract 334.
50. Nooka AK, et al. Thalidomide as maintenance therapy in multiple myeloma (MM) improves progression free survival (PFS) and overall survival (OS): A meta-analysis. ASH Annual Meeting Abstracts 2011;118:1855.
51. Hahn-Ast C, et al. Improved progression-free and overall survival with thalidomide maintenance therapy after autologous stem cell transplantation in multiple myeloma: a meta-analysis of five randomized trials. Haematologica 2011;96(Suppl 1).
52. Ludwig H, et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood 2012;119:3003–15.
53. Morgan GJ, et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 2012;119:7–15.
54. Attal M, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1782–91.
55. McCarthy PL, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1770–81.
56. Mellqvist UH, et al. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood 2013;121:4647–54.
57. Cavo M, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 2012;120:9–19.
58. Palumbo A, et al. Overall survival benefit for bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in newly diagnosed multiple myeloma patients. ASH 2012: Abstract 200.
59. Palumbo A, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 2010;28:5101–9.
60. Bensinger WI, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors and outcome. Blood 1996;88:2787–93.
61. Einsele H, et al. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol 2003;121:411–8.
62. Bruno B, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007;356:1110–20.
63. Gahrton G, et al. Autologous/reduced-intensity allogeneic stem cell transplantation versus autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood 2013;121:5055–63.
64. Garban F, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99–03 trial) with tandem autologous stem cell transplantation (IFM99–04 trial) in high-risk de novo multiple myeloma. Blood 2006;107:3474–80.
65. Krishnan A, et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 2011;12:1195–203.
66. Ludwig H, et al. European perspective on multiple myeloma treatment strategies: update following recent congresses. Oncologist 2012;17:592–606.
67. Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011;86:57–65.
68. Mohty B, et al. Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and „retreatment“ approaches in the era of novel agents. Leukemia 2012;26:73–85.
69. Dimopoulos MA, et al. Analysis of second-line lenalidomide following initial relapse in the MM-015 trial. ASH Annual Meeting Abstracts 2012;120:944.
70. Dimopoulos MA, et al. Pomalidomide in combination with low-dose dexamethasone: Demonstrates a significant progression free survival and overall survival advantage, in relapsed/refractory MM: A phase 3, multicenter, randomized, open-label Study. ASH Annual Meeting Abstracts 2012;120:LBA-6.
71. Richardson PG, et al. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood 2013;121:1961–7.
72. Vij R, et al. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol 2012;158:739–48.
Modifizierter Nachdruck aus Med Monatsschr Pharm 2014;37:84–92.
Priv.-Doz. Dr. med. Stefan Knop, Medizinische Klinik und Poliklinik II, Zentrum für Innere Medizin, Josef-Schneider-Straße 2, 97080 Würzburg, E-Mail: Knop_S@medizin.uni-wuerzburg.de